Sumitomo Pharma Co.ltd. · TSE:4506

Sumitomo Pharma Co.ltd — Q2 2025 Earnings Presentation

29 slides from Sumitomo Pharma Co.ltd's earnings presentation, Oct 31, 2025

  1. Slide 1: Conference on Q2 FY2025 Financial Results

    Conference on Q2 FY2025 (April 1, 2025 to September 30, 2025) Financial Results Toru Kimura, President and CEO Sumitomo Pharma Co., Ltd. October 31, 2025

  2. Slide 2: Disclaimer Regarding Forward-looking Statements

    Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group’s financial results and other data. Such forward-looking statements are based on the Company’s assumptions, estimates, outlook, and ot

  3. Slide 3: Financial Results for Q2 FY2025

    Financial Results for Q2 FY2025 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 2

  4. Slide 4: Financial Results for Q2 FY2025 (Core Basis)

    Financial Results for Q2 FY2025 The forecasts for FY2025 were revised Financial Results for Q2 FY2025 (Core Basis) (See P.8) Billions of JPY Q2YTD Q2YTD Change FY2025  Revenue increased primarily due FY2024 FY2025 July 31 1H to the growth of ORGOVYX® and Results Results Value FX impact % % Forecast

  5. Slide 5: Revenue of Major Products in North America

    Financial Results for Q2 FY2025 Revenue of Major Products in North America Q2YTD Q2YTD Q2YTD Q2YTD Change FY2025 FY2024 FY2025 Change FY2024 FY2025 JPY-basis FX Results Results Results Results Value % May 13 forecasts impact Progess % Millions Billions North America Millions of USD Billions of JPY o

  6. Slide 6: Revenue of Major Products in Japan

    Financial Results for Q2 FY2025 Revenue of Major Products in Japan Billions of JPY Q2YTD Q2YTD Change FY2025 FY2024 FY2025 May 13 Progress Results Results Value ％ forecasts % Japan LATUDA® 6.7 6.9 0.2 3.6 13.5 51.1 TWYMEEG® 3.6 5.0 1.4 40.3 11.2 44.5  TWYMEEG® revenue continued to grow METGLUCO® 3.

  7. Slide 7: Segment Information (Core Basis)

    Financial Results for Q2 FY2025 Segment Information (Core Basis) Billions of JPY North Japan America Asia Total Japan Revenue 46.9 163.0 17.3 227.1  Despite the decline of gross profit due to lower revenue, Cost of sales core segment profit increased due to SG&A expense 24.5 61.2 4.1 89.7 reduction

  8. Slide 8: Forecasts for FY2025

    Financial Forecasts for FY2025 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 7

  9. Slide 9: Financial Forecasts for FY2025 (Core Basis)

    Financial Forecasts for FY2025 Financial Forecasts for FY2025 (Core Basis) FX rates: Billions of JPY FY2025 FY2025 FY2025 Change from Previous Previous Forecasts : 1US$ = ¥145.00, 1RMB = ¥20.00 May 13 Revised forecasts Revised Forecasts : 1US$ = ¥145.00, 1RMB = ¥20.12 Forecasts Forecasts Value % Rev

  10. Slide 10: Revenue of Major Products in North America

    Financial Forecasts for FY2025 Revenue of Major Products in North America FY2025 FY2025 FY2025 FY2025 FX rates: Not changed Change FY2025 Forecasts : 1US$ = ¥145.00 May 13 Revised Change May 13 Revised Forecasts Forecasts Forecasts Forecasts Value % North America Millions of USD Billions of JPY  Sa

  11. Slide 11: ORGOVYX®

    Financial Forecasts of FY2025 ORGOVYX®  Q2 YTD: Achieved 133% of net sales versus original forecast primarily driven by solid patient growth from Jan. 2025 Revised annual sales forecast upward to $1,020M (+$310M) Plan for Q2 Actual for Q2 Year-over-year Variance Analysis YTD FY2025 YTD FY2025 compa

  12. Slide 12: MYFEMBREE®

    Financial Forecasts of FY2025 MYFEMBREE®  Q2 YTD: Achieved 103% of net sales versus original forecast primarily driven by stable volume even after the termination of collaboration. Annual forecast remains at $85M  Achieved profitable product contribution through optimization of SG&A investments (e

  13. Slide 13: GEMTESA®

    Financial Forecasts of FY2025 GEMTESA®  Q2 YTD: Achieved 109% of net sales versus original forecast primarily driven by increased volume since March 2025 Revised annual sales forecast upward to $588M (+$16M) Plan for Q2 Actual for Q2 Year-over-year Variance Analysis YTD FY2025 YTD FY2025 comparison

  14. Slide 14: Segment Information (Core Basis)

    Financial Forecasts for FY2025 Segment Information (Core Basis) Billions of JPY Japan North America Asia Total Japan Revenue 92.5 313.6 22.9 429.0  Profit expected to increase due to increase of FY2025 Revised Cost of sales 48.8 128.9 8.8 186.5 gross profit and reduction in SG&A expenses Forecasts

  15. Slide 15: Marketing and Sales in Japan: Co-Promotion Agreement with Novo Nordisk Pharma

    Marketing and Sales in Japan Transition to a Sales Structure Specialized on Priority Therapeutic Areas (from Oct. 2025)  Transitioned from a regional-based structure to a therapeutic-area-based structure to drive more strategic and agile sales activities in our focus areas—CNS, diabetes (including

  16. Slide 16: Research and Development

    Research and Development © Sumitomo Pharma Co., Ltd. All Rights Reserved. 15

  17. Slide 17: Development Pipeline (as of October 31, 2025)

    Research and Development Development Pipeline (as of October 31, 2025) Revisions since the announcement in July 2025 are shown in red Area Generic name/Product code Mechanism of action, etc. Planned indication(s) Development stage Serotonin 5-HT2A receptor antagonist and serotonin DSP-0038 Alzheimer

  18. Slide 18: Major Topics in Clinical Development

    Research and Development Major Topics in Clinical Development  Psychiatry & Neurology (Regenerative medicine/cell therapy)  Allogeneic iPS cell-derived dopaminergic neural progenitor cells (U.S., Japan) (collaboration with RACTHERA) • Parkinson’s disease MAA submitted in Japan in August 2025 based

  19. Slide 19: enzomenib (DSP-5336) Acute leukemia

    Research and Development Data cutoff: March 27, 2025 Oncology: enzomenib（DSP-5336）Acute leukemia (Oral presentations data at the Japanese Society of Hematology 2025 )  Efficacy in the Japanese population was similar to that of the overall population  In both the overall population and the Japanese

  20. Slide 20: Anti-LAH Antibody Titers

    Research and Development Other areas: fH1/DSP-0546LP Influenza virus prophylaxis  Europe Phase1 Study Overview Antibody Induction Against a Novel Epitope (LAH*) • Objective: Evaluation of safety, tolerability, and immunogenicity (antibody titers, antiviral activity, cross-reactivity) • Subjects: 14

  21. Slide 21: Contents

    ＜Contents＞ Appendix P.21 Q2FY2025 P.22 Q2FY2025 Financial Results for Q2 FY2025 (Full Basis) Financial Position and Cash Flow P.23 Q2FY2025 Prescription Trends of GEMTESA® P.24 Financial Forecasts for FY2025 Revenue of Major Products in Japan P.25 R&D Main Events/Targets for FY2025 P.26 R&D Product

  22. Slide 22: Financial Results for Q2 FY2025 (Full Basis)

    Appendix (Financial Results for Q2 FY2025) Financial Results for Q2 FY2025 (Full Basis) Billions of JPY Q2YTD Q2YTD Change FY2024 FY2025 Results Results Value ％ Revenue 180.7 227.1 46.4 25.7 Cost of sales 72.3 89.7 17.4 24.0 Gross profit 108.4 137.4 29.0 26.7 SG&A expenses 90.0 76.6 (13.4) (14.9) R&

  23. Slide 23: Financial Position and Cash Flow

    Appendix (Financial Results for Q2 FY2025) Financial Position and Cash Flow Billions of JPY As of March As of Sep. Ｂ/Ｓ Change 2025 2025 Assets 742.6 778.4 35.8 Increase in investments accounted for using the equity method Other non-current assets 28.2 54.7 26.5 Trade and other receivables 74.8 124.5

  24. Slide 24: Prescription Trends of GEMTESA®

    Appendix (Financial Results for Q2 FY2025) Prescription Trends of GEMTESA®  Despite the launch of Mirabegron generics in April 2024, the total number of GEMTESA® prescriptions and new prescriptions continued to increase. However, since Jan. 2025, there was a slight decline due to changes in Medicar

  25. Slide 25: Revenue of Major Products in Japan

    Appendix (Financial Forecasts for FY2025) Revenue of Major Products in Japan Billions of JPY FY2025 FY2025 Change May 13 Revised Japan Value ％ Forecasts Forecasts Japan LATUDA® 13.5 13.5 － － TWYMEEG® 11.2 11.2 － － METGLUCO® 7.6 7.5 (0.1) (1.3)  Sales of EquMet® revised upward due to change in its ®

  26. Slide 26: Main Events / Targets for FY2025

    Appendix (Research and Development) Main Events / Targets for FY2025 (as of October 31, 2025)  Allogeneic iPS cell-derived products (Parkinson’s disease): Obtain approval in Japan ⇒MAA submitted (Aug. 2025) Psychiatry  Allogeneic iPS cell-derived products (Parkinson’s disease): Advance Phase 1/2 s

  27. Slide 27: Product Launch Target (as of October 31, 2025)

    Appendix (Research and Development) Psychiatry & Product Launch Target (as of October 31, 2025) Neurology Oncology Others FY2025 2026 2027 2028 2029 Allogeneic iPS cell-derived dopaminergic neural progenitor Parkinson’s disease Development cells（CT1-DAP001/DSP-1083） in the U.S (RACTHERA Co., Ltd.) A

  28. Slide 28: Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline

    Appendix (Research and Development) Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline(RACTHERA Co., Ltd.) (as of October 31, 2025) Revisions since the announcement in July 2025 are shown in red Brand name/Cell type JP/ Clinical Approval Approval→ Indications Pre-clinical P

  29. Slide 29: Sumitomo Pharma

    < Sumitomo Pharma Innovation today, healthier tomorrows

Sumitomo Pharma — Q2 2025 Earnings Presentation on 6ix